Turn an agreed change into a delivery case.

NICE's formulary guidance includes decision outputs and review processes (NICE, 2014). A local implementation exercise needs to identify the specific documents and workflows affected by an agreed change. These may include prescribing guidance, stock arrangements, patient information and service communications. An action list should distinguish essential dependencies from improvements that can follow later. The goal is not to produce a larger project plan; it is to prevent a small omission from leaving different teams working from incompatible versions of the same decision.

The implementation case should explain what different people need to know. A prescriber, dispensary team and person receiving care will not need the same message. NICE's shared decision-making guidance gives relevant context for understandable information and involvement (NICE, 2021). Our proposed organisational task would map communication responsibilities and review requirements, without drafting individual treatment advice. Include accessible formats and the handling of questions. A change is easier to deliver when the plan anticipates where explanation and support will actually be required.

A bounded PHARMORIS evaluation could use an approved historical decision and its supporting documents to prepare an implementation brief. Compare it with the existing action tracker and planning templates. Independent reviewers would identify essential dependencies, role assignments and evidence needed for closure. The exercise could begin without patient-level data or live system changes. It would test whether the proposed support finds omissions and clarifies work, rather than assuming that a more elaborate plan necessarily improves implementation.

Stop if the draft assigns responsibility to a role that has not accepted it, treats an issued document as proof of adoption or misses an essential safety dependency. Reassess if maintaining the proposed plan creates more work than the current method. A useful output may reveal that the principal obstacle is capacity or agreement between organisations. PHARMORIS should be evaluated for the tasks it can reasonably support; it cannot make a disputed policy operational merely by presenting it attractively.

A formulary pharmacist, provider medicines lead and operational representative can define a decision that has already been made and the implementation work still open. We can discuss a source-linked preparation comparison with agreed review criteria. The potential commercial incentive is a repeatable way to make delivery requirements clearer across medicines changes. That remains a development proposition. A pilot would need to demonstrate useful quality and effort against the tools the team already trusts before wider adoption could be considered.